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Head and neck cancers in AustraliaHead and neck cancers in Australia, presents the latest available information on incidence, mortality, survival 
and hospitalisations.
Findings include:
•   The total number of head and neck cancers diagnosed 
in 2009 was 3,896 accounting for 3.4% of all cancers 
diagnosed (114,137).
•   The total number of deaths from head and neck  
cancers in 2011 was 944 accounting for 2.2% of all 
deaths from cancer (43,221).
•   In 2006–2010, 5–year relative survival was 68.2% for all 
head and neck cancers combined.
•   In 2011–12 there were 8,478 hospitalisations where 
head and neck cancer was the principal diagnosis.
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1. Summary 
Head and neck cancer is a term used to describe a range of cancers that occur in the throat 
(pharynx and larynx), nose, sinuses and mouth. 
This report presents the most recent data available on head and neck cancer incidence, 
mortality, survival and hospitalisations and also describes risk factors that can contribute to 
a person developing head and neck cancer. 
The report also includes a ‘spotlight’ section which discusses the human papillomavirus 
(HPV) and how it contributes to head and neck cancers. 
Incidence 
The number of head and neck cancers diagnosed in Australia is increasing. From 1982 to 
2009, the number of head and neck cancers diagnosed rose from 2,475 to 3,896.  
While the number of cases diagnosed is rising, the age-standardised incidence rate for head 
and neck cancers fell from 19.3 per 100,000 persons in 1982 to 16.8 per 100,000 in 2009. 
Increases in the overall number of cases diagnosed are occurring, despite decreases in  
age-standardised incidence rates, because of Australia’s increasing and ageing population. 
The number of cases diagnosed in 2009 was higher for males than females. Males accounted 
for 73.8% (2,875) of head and neck cancers compared to 26.2% (1,021) for females. 
Mortality 
Similar to the number of cases diagnosed, the number of deaths from head and neck cancers 
rose from 752 in 1982 to 944 in 2011. 
The age-standardised mortality rate fell from 6.1 per 100,000 persons in 1982 to 3.8 per 
100,000 in 2011. Increases in the overall number of deaths due to head and neck cancers are 
occurring, despite a drop in the age-standardised mortality rates, because of the growth and 
ageing of Australia’s population. 
Males accounted for a higher number of deaths in 2011 than females, with 73.2% (691) of 
deaths from head and neck cancers among males compared to 26.8% (253) for females. 
Survival 
Overall survival from head and neck cancers is improving. There was a rise in 5-year relative 
survival from 61.8% in 1982–1987 to 68.2% in 2006–2010. One-year relative survival for males 
and females in 2006–2010 were broadly comparable. However, 5-year relative survival for 
females was higher at 70.4% compared to males at 67.4%. 
Hospitalisations 
Hositalisations for head and neck cancers are also rising. In 2011–12, there were 8,478 
hospitalisations where head and neck cancer was the principal diagnosis. This was an 
increase of 13.8% from 2002–03 when there were 7,448 hospitalisations. 
The number of hospitalisations for surgery where head and neck cancer was the principal 
diagnosis also increased over time, from 3,305 in 2002–03 to 3,725 in 2011–12. This was an 
overall increase of 12.7%. 
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2. Introduction 
This report is one of a series of brief reports being developed under the framework of the 
National Centre for Monitoring Cancer under the guidance of the Cancer Monitoring 
Advisory Group. 
Other reports planned in the series include: 
• Skin cancer 
• Cancer and mental health 
• Haematological (blood) cancers. 
Each report will incorporate a ‘spotlight’ section which highlights a particular issue 
associated with a specific cancer or cancer-related topic. 
This report, the first in the series, is about head and neck cancers with a spotlight on the 
human papillomavirus (HPV), and its link with head and neck cancers.  
Cancer (also called malignant neoplasm) is a diverse group of diseases characterised by the 
uncontrolled proliferation of abnormal cells. These abnormal cells invade and damage the 
tissues around them, and may then spread to other parts of the body, which can cause 
further damage and eventually death (AIHW 2012). 
Cancers are distinguished from each other by the location in the body in which the disease 
began (known as the site) and/or by the type of cell involved (known as histology). For 
example, cancer that begins in the lung is called lung cancer, regardless of whether or not it 
has spread to other sites. The original site in which a cancerous tumour is formed is referred 
to as the primary cancer. The spread of cancerous cells from the primary cancer site to 
another (that is, secondary) site is referred to as metastasis (see Glossary) (AIHW 2012). 
The term ‘head and neck cancer’ does not refer to a single type of cancer—it is a term used to 
describe a range of malignant (cancerous) tumours that can appear in or around the throat 
(pharynx and larynx), nose, sinuses and mouth (NCI 2013). 
There are 18 different cancer sites categorised as head and neck cancers according to the 
International Classification of Diseases (ICD-10) (see Appendix A). 
This report presents these cancers in the following 5 head and neck cancer groups: 
• Oral cavity 
• Salivary glands 
• Pharynx 
• Nasal cavity and paranasal sinus 
• Larynx (see Figure 2.1). 
Head and neck cancers also include a sixth group, ‘ill-defined sites in the lip, oral cavity and 
pharynx’. Totals of all head and neck cancers discussed in this report include this group but 
it is not presented separately. 
The glossary provides definitions of what is included in each of the 5 head and neck cancer 
groups. 
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Figure 2.1: Head and neck cancer regions 
This report presents the latest available data on head and neck cancers, comprising: 
• Incidence data 2009 
• Mortality data 2011 
• Survival data 2006–2010 
• Hospitalisations data 2011–12. 
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3. Facts about head and neck cancers 
There are 18 different cancer sites categorised as head and neck cancers. Cancers that are 
known collectively as head and neck cancers usually begin in the squamous cells (the 
uppermost skin cells) that line the moist, mucosal surfaces inside the head and neck (NCI 
2013). It is not uncommon that a patient may have multiple cancers in different regions of the 
head and neck. 
Dental practitioners, as well as general practitioners, often diagnose head and neck cancers. 
Males account for a much higher proportion of diagnosed head and neck cancers compared 
with females. 
Head and neck cancers are often associated with lifestyle risk factors. Factors that can 
increase an individual’s risk of developing head and neck cancers include: 
• genetic predisposition 
• behaviour—such as smoking, excess alcohol consumption, diet and physical inactivity 
• obesity 
• environmental and occupational hazards (Langevin et al. 2013). 
Also, viruses, such as Epstein–Barr virus and Cytomegalovirus, have links to head and neck 
cancers (Paradise et al. 2013). 
Additionally, high risk types of human papillomavirus (HPV), including HPV-16, can 
increase the risk of developing some head and neck cancers (Gillison et al. 2008; Kreimer et 
al. 2013). 
HPV and its link to head and neck cancers is discussed in more detail in the ‘spotlight’ 
section. 
Risk factors  
 
Tobacco use 
Smoking is a major risk factor for some head and neck cancers, particularly the larynx, oral 
cavity, oropharynx and hypopharynx (NCI 2013). 
In 1985, a working group under the International Agency for Research on Cancer (IARC) 
recognised a causal link between tobacco smoking and cancers including oral cavity, 
pharynx and larynx. Seventeen years later, the IARC added cancers of the nasal cavities and 
nasal sinuses to the list of smoking-related head and neck cancers (Gandini et al. 2008). 
The percentage of males aged 14 years or older in Australia who were daily smokers 
decreased steadily from 58% in 1964 to 16.4% in 2010. For females aged 14 years or older, the 
percentage of daily smokers increased from 28% in 1964, peaking at 32.5% in 1976 before 
falling to 13.9% in 2010 (Figure 3.1). 
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Note: The data for this figure are in Table A1. 
Source: OECD health data, 2013. 
Figure 3.1: Trends in smoking rates by sex, Australia, 1964–2010 
Tobacco has been identified as a major carcinogenic factor in the overwhelming majority of 
squamous cell carcinomas in the head and neck (Sturgis et al. 2004). The risk for squamous 
cell cancer of the head and neck is estimated to be approximately 10-fold greater for current 
smokers compared with never-smokers. This risk decreases with time from the cessation of 
exposure, although the risk never reduces to the level of a never-smoker (Schlecht et al. 
1999). 
Both smoking (cigarettes, cigars, and pipes) and ‘smokeless’ tobacco (snuff and chewing 
tobacco) increase the risk of developing oral cancer (Ko et al. 1995; Rodu & Jansson 2004). 
As tobacco use is a major risk factor for some head and neck cancers, trends in the incidence 
of head and neck cancers are likely to follow smoking trends, noting the lag in time between 
smoking and the onset of cancer. 
 
Alcohol consumption 
There is strong scientific evidence that alcohol increases the risk of mouth and throat cancer. 
The World Cancer Research Fund recommendation is not to drink alcoholic drinks. The 
National Health and Medical Research Council guidelines recommend that healthy men and 
women not drink more than two standard drinks on any day. This reduces the risk of 
alcohol-related harm over a lifetime (NHMRC 2014). 
Studies have shown that heavy consumption of alcohol is associated with nutrient 
deficiency, which appears to contribute independently to some head and neck cancers. 
Alcohol consumption and smoking can also have a synergistic effect on cancer risk, meaning 
the combined effects are significantly greater than individual risks added together (Reidy et 
al. 2011). 
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At least 75% of head and neck cancers are attributable to a combination of cigarette smoking 
and alcohol drinking (Hashibe et al. 2007). In 2010, 38% of Australians aged 14 years or older 
who were current smokers also consumed alcohol at risky levels (more than 2 standard 
drinks a day on average), compared to only 12% of people who had never smoked (AIHW 
analysis of the 2010 NDSHS). 
 
Sun exposure  
Australia has one of the highest rates of skin cancer of any country in the world (Montague 
et al. 2001). Exposure to the sun can cause head and neck cancer, particularly cancer of the 
lip. 
 
Diet 
Gastroesophageal reflux—acid from the stomach travelling up into the oesophagus increases 
your risk of developing oesophageal cancer (WCRF 2012). 
Studies suggest an association with certain foods including salted fish and some preserved 
foods and hot spices. The carcinogenic potential of salt-preserved food can be explained by 
the accumulation of significant levels of nitrosamines, which are known for their 
carcinogenic properties (Tabuchi et al. 2011). 
Diet can contribute to orophangeal cancer. A higher quantity intake of fruits and vegetables 
is also associated with reduced incidence of oesophageal squamous carcinoma and 
adrenocarcinoma (Holmes & Vaughan 2007). 
 
Family history and genetic susceptibility 
 
Genetic predisposition and family history (for example, a first-degree relative having head 
and neck cancer) may play a role in head and neck cancer (Negri et al. 2009). A first-degree 
relative is a family member who shares about 50 per cent of their genes with a particular 
individual in a family (mother, father, sister, brother, daughter, son). 
Numerous studies have been conducted to investigate genetic mechanisms in cancer causes 
and pathogenesis. Some studies suggest slight differences in certain gene segments make 
some individuals more prone to developing cancer, which is known as ‘genetic 
susceptibility’(Zavras & Yoon 2013). 
For example, nasopharyngeal carcinoma is quite rare in most populations, but it is a leading 
form of cancer in a few well-defined populations, including natives of southern China, 
south-east Asia, the Arctic, and the Middle East/north Africa (Chang & Adami 2006). 
 
Obesity and physical inactivity 
Evidence suggests that modifications to a number of lifestyle factors, including physical 
exercise and weight loss, have the potential to reduce head and neck cancer incidence 
(WCRF/AICR 2007). 
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Environmental and occupational exposures 
Environmental and occupational factors including asbestos, wood dust and leather dust can 
also contribute to some head and neck cancers, including in the larynx and pharynx 
(Langevin et al. 2013). 
 
Viruses 
The human papillomavirus (HPV) has been recognised as contributing to some cancers of 
the head and neck. The high-risk HPVs have been linked to cancers affecting oral cavity and 
pharynx (the area at the back of the throat). 
Also, viruses, such as Epstein–Barr virus and Cytomegalovirus have links to head and neck 
cancers (Paradise et al. 2013). 
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4. Incidence of head and neck cancers 
Head and neck cancer incidence refers to the number of new cases of head and neck cancers 
diagnosed during a specific period, usually 1 year. It does not refer to the number of people 
newly diagnosed (because 1 person can be diagnosed with more than 1 head or neck cancer 
in a year), although the 2 numbers are likely to be similar. 
Head and neck cancer incidence data come from the Australian Cancer Database, which 
contains information on Australians diagnosed with primary, invasive cancer (excluding 
basal cell and squamous cell carcinomas of the skin) since 1982. 
Incidence of head and neck cancers combined 
Number of new cases diagnosed 
• The total number of head and neck cancers diagnosed in 2009 was 3,896, accounting for 
3.4% of all cancers diagnosed (114,137). 
• Males accounted for a much higher proportion of head and neck cancers, accounting for 
73.8% of new cases diagnosed in 2009. 
• From 1982 to 2009, the number of head and neck cancers diagnosed generally increased 
from 2,475 (1,943 males and 532 females) to 3,896 (2,875 males and 1,021 females) (Table 
A2 and A3). 
Incidence rates 
• From 1982 to 2009, the age-standardised incidence rate for head and neck cancers in all 
persons (males and females combined) decreased from 19.3 per 100,000 persons to 16.8 
per 100,000 persons. 
• This decrease was mainly due to a reduction in the incidence rate for males from 32.4 per 
100,000 in 1982 to 25.9 per 100,000 in 2009. 
• In females, the incidence rate from 1982 to 2009 remained relatively stable at around 8 
per 100,000 (Figure 4.1). 
 8 Head and neck cancers in Australia 
 
Notes 
1.  Cancers coded in ICD-10 as C00–C14, C30–C32. 
2.  Rates are age-standardised to the estimated resident population of Australia for 30 June 2001. 
3.  The data for this figure are in Table A3. 
Source: AIHW Australian Cancer Database 2009.  
Figure 4.1: Trends in the number of cases diagnosed and incidence rate, all head and neck cancers 
combined, by sex, Australia, 1982–2009 
Incidence of head and neck cancer groups 
In 2009, the number of new cancer cases for each of the head and neck cancer groups were: 
• Oral cavity with 2,037. This was 52.3% of all new cancers diagnosed in 2009 
• Pharynx with 739 (19.0%) 
• Larynx with 606 (15.6%) 
• Salivary glands with 265 (6.8%) 
• Nasal cavity and paranasal sinus with 166 (4.3%). 
Males accounted for at least 60% of new cases in each head and neck group in 2009. 
From 1982 to 2009, the number of new cases diagnosed for head and neck cancer groups 
increased by varying degrees: 
• Oral cavity from 1,263 to 2,037 
• Pharynx from 378 to 739 
• Larynx from 553 to 606 
• Salivary glands from 152 to 265 
• Nasal cavity and paranasal sinus from 96 to 166 (Figure 4.2). 
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Notes 
1. Cancers coded in ICD-10 as C00–C14, C30–C32. 
2. The data for this figure are in Table A4. 
Source: AIHW Australian Cancer Database 2009.  
Figure 4.2: Trends in number of cases, groups of head and neck cancers, persons, Australia,  
1982–2009 
 
Internationally, according to the World Health Organization, oral cancers are more common 
in parts of the world where betel quid is chewed. Of the 390,000 oral and oropharyngeal 
cancers estimated to occur annually in the world, 228,000 (58%) occur in south and  
south-east Asia. Evidence in Taiwan and China, where the incidence of oral cancer in men 
has tripled since the early 1980s, coincides with the practice of chewing betel quid (WHO 
2003). 
Nasopharyngeal cancer (a cancer included in the Pharynx group) is distinctive due to its 
peculiar epidemiological and biological characteristics. Nasopharyngeal cancer is a rare 
cancer in most parts of the world, but occurs at a high rate in south-east Asia (Wang et al. 
2012). 
Incidence rates of nasopharyngeal are highest in south-eastern Asia (Jemal et al. 2011). The 
distinctive racial/ethnic and geographic distribution of nasopharyngeal carcinoma 
worldwide suggests that both environmental factors and genetic traits contribute to its 
development (Chang & Adami 2006). 
In 2009, a total of 122 nasopharyngeal cancers were diagnosed in Australia. Of these, 45 were 
diagnosed in people born in north-east Asia or south-east Asia (37%). In comparison, the 
proportion of Australians who were born in north-east Asia or south-east Asia in 2011 was 
only 3.25%. 
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Incidence rates of head and neck cancer groups 
After adjusting for changes in the age structure of the population over time, changes in the 
age-standardised incidence rate varied from year to year for head and neck cancer groups 
from 1982 to 2009: 
• Oral cavity incidence rates generally increased from 9.9 per 100,000 persons in 1982 to 
12.1 per 100,000 persons in 1992. The incidence rate then decreased to 8.8 per 100,000 
persons in 2009. 
• Pharynx rates increased slightly from 2.9 per 100,000 in 1982 to 3.2 per 100,000 in 2009. 
• Larynx rates decreased from 4.3 per 100,000 to 2.6 per 100,000. 
• Salivary gland rates remained relatively stable at around 1.2 per 100,000. 
• Nasal cavity and paranasal sinus rates also remained relatively stable at around 0.8 per 
100,000 (Figure 4.3). 
 
 
Notes 
1.  Cancers coded in ICD-10 as C00–C14, C30–C32. 
2.  Rates are age-standardised to the estimated resident population of Australia for 30 June 2001. 
3.  The data for this figure are in Table A4. 
Source: AIHW Australian Cancer Database 2009.  
Figure 4.3: Trends in incidence rates, groups of head and neck cancers, persons, Australia,  
1982–2009 
The increase in the number of head and neck cancers diagnosed over time can be explained, 
at least in part, by the increasing size and ageing of the population. Any change in  
age-standardised incidence rates may reflect alterations to lifestyles and health behaviours 
such as reduced smoking rates within the population. 
The Australian Cancer Database Data Quality Statement can be found at Appendix B. 
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5. Mortality from head and neck cancers 
Mortality refers to the number of deaths for which the underlying cause of death was a head 
or neck cancer. The head and neck cancer that led to the death of the person may have been 
diagnosed many years previously, in the same year in which the person died or, in some 
cases, after death (for example at autopsy). Information on underlying cause of death is 
derived from the medical certificate for cause of death, which a medical practitioner usually 
completes. 
The mortality data source used in this report is the AIHW National Mortality Database 
which contains information about all deaths registered in Australia since 1964. 
Number of deaths from head and neck cancers 
combined 
Number of deaths 
• The total number of deaths from head and neck cancers in 2011 was 944, accounting for 
2.2% of all deaths from cancer (43,221). 
• Males accounted for a much higher proportion of deaths from head and neck cancers 
with 691 deaths (73.2%) compared to 253 for females (26.8%) (Figure 5.1). 
• From 1982 to 2011, the number of deaths from head and neck cancers trended upwards 
from 752 (570 males and 182 females) to 944 (691 males and 253 females) (Tables A2 and 
A3). 
Mortality rates 
• From 1982 to 2011, the age-standardised mortality rate for head and neck cancers 
decreased from 6.1 deaths per 100,000 persons to 3.8 deaths per 100,000 persons. 
• The decrease in the mortality rate from 1982 to 2011 was more pronounced for males 
than females, with the mortality rate for males falling from 10.0 deaths per 100,000 
persons in 1982 to 6.0 deaths per 100,000 persons in 2011. 
• Over the same period, the mortality rate for females dropped from 2.8 deaths per 100,000 
persons to 1.8 deaths per 100,000 persons (Figure 5.1). 
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Notes 
1. Deaths registered in 2009 and earlier are based on the final version of cause of death data; deaths registered in 2010 and 2011 are subject 
to further revision. 
2. Cancers coded in ICD-10 as C00–C14, C30–C32. 
3. Rates are age-standardised to the estimated resident population of Australia for 30 June 2001. 
4. The mortality data in AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the National 
Coronial Information System and coded by the Australian Bureau of Statistics. 
5. Years in table refer to year of occurrence of death except for the most recent year, which refers to the year of registration of death.  
6. The data for this figure are in Table A3. 
Source: AIHW National Mortality Database.  
Figure 5.1: Trends in the number of deaths and mortality rates for all head and neck cancers 
combined, by sex, Australia, 1982–2011 
Number of deaths in head and neck cancer groups 
In 2011, the total number of deaths from head and neck cancer was 944. The number of 
deaths allocated into head and neck cancer groups followed the same order as cancer 
incidence numbers: 
• Oral cavity with 294 (31.1% of all deaths from head and neck cancer) 
• Pharynx with 238 (25.2%) 
• Larynx with 207 (21.9%) 
• Salivary glands with 79 (8.4%) 
• Nasal cavity and paranasal sinus with 37 (3.9%). 
Males accounted for a much higher proportion of deaths in each of the head and neck cancer 
groups, accounting for at least 61% of deaths for each group in 2011. 
From 1982 to 2011, the number of deaths for each head and neck cancer group inreased 
except for nasal cavity and paranasal sinus which decreased: 
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• Oral cavity increased from 237 deaths in 1982 to 294 deaths in 2011 
• Pharynx increased from 217 deaths to 238 deaths 
• Larynx increased from 192 deaths to 207 deaths 
• Salivary glands increased from 40 deaths to 79 deaths 
• Nasal cavity and paranasal sinus decreased from 47 deaths to 37 deaths (Figure 5.2). 
 
Notes 
1. Deaths registered in 2009 and earlier are based on the final version of cause of death data; deaths registered in 2010 and 2011 are subject 
to further revision. 
2. Cancers coded in ICD-10 as C00–C13, C30–C32. 
3. The mortality data in AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the National 
Coronial Information System and coded by the Australian Bureau of Statistics. 
4. Years in table refer to year of occurrence of death except for the most recent year, which refers to the year of registration of death.  
5. The data for this figure are in Table A5. 
Source: AIHW National Mortality Database. 
Figure 5.2: Trends in number of deaths, groups of head and neck cancers, persons, Australia,  
1982–2011 
Mortality rates for head and neck cancer groups 
From 1982 to 2011, mortality rates for head and neck cancer groups remained relatively 
stable over time: 
• Oral cavity at around 1.5 deaths per 100,000 persons 
• Pharynx at around 1.2 deaths per 100,000 
• Larynx at around 1.2 deaths per 100,000 
• Salivary glands at around 0.3 deaths per 100,000 
• Nasal cavity and paranasal sinus at around 0.2 deaths per 100,000 (Figure 5.3). 
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Notes 
1. Deaths registered in 2009 and earlier are based on the final version of cause of death data; deaths registered in 2010 and 2011 are subject 
to further revision. 
2. Cancers coded in ICD-10 as C00–C13, C30–C32. 
3. Rates are age-standardised to the estimated resident population of Australia for 30 June 2001. 
4. The mortality data in AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the National 
Coronial Information System and coded by the Australian Bureau of Statistics. 
5. Years in table refer to year of occurrence of death except for the most recent year, which refers to the year of registration of death.  
6. The data for this figure are in Table A5. 
Source: AIHW National Mortality Database.  
Figure 5.3: Trends in mortality rates, groups of head and neck cancers, persons, Australia, 1982–2011 
The data quality statements underpinning the National Mortality Database can be found in 
quality declaration summaries in the following ABS catalogues: 
<http://www.abs.gov.au/AUSSTATS/abs@.nsf/mf/3303.0/> 
<http://www.abs.gov.au/ausstats/abs@.nsf/mf/3302.0>. 
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6. Survival from head and neck cancers 
Information about survival from cancer provides an indication of cancer prognosis and the 
effectiveness of the treatments available. A range of factors influence survival from cancer 
including the demographic characteristics of the patient (such as age, sex and genetics), the 
nature of the tumour (such as site, stage at diagnosis and histology type) and the health-care 
system (such as the availability of health-care services, diagnostic and treatment facilities, 
and follow-up services). 
Survival in this report refers to ‘relative survival’ that is, all survival probabilities presented 
are relative to those of the general population. It refers to the probability of being alive for a 
given amount of time after diagnosis compared to those of the general population, and 
reflects the impact of a cancer diagnosis.  
Survival for head and neck cancers combined 
In 2006–2010, 5-year relative survival was 68.2% for all head and neck cancers combined. 
This means that people diagnosed with these cancers had a 68.2% chance of surviving for at 
least 5 years compared with the general population. This is an increase from 1982–1987 when 
5-year relative survival for head and neck cancers was 61.8%. 
Females had slightly lower 1-year relative survival than males (86.3% for females and 86.7% 
for males) but higher 5-year survival than males, at 70.4% compared with 67.4% for males 
(Figure 6.1). 
 
Notes 
1. Cancers coded in ICD-10 as C00–C14, C30–C32. 
2. The data for this figure are in Table A6. 
Source: AIHW Australian Cancer Database 2007. 
Figure 6.1: Five-year relative survival, all head and neck cancers combined, by sex, Australia,  
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Survival for head and neck cancer groups 
In 2006–2010, 5-year relative survival was highest for oral cavity cancer. 5-year relative 
survival for all head and neck cancer groups was: 
• Oral cavity at 75.0% (75.6% males and 73.8% females) 
• Pharynx at 55.5% (54.8% for males and 58.2% for females) 
• Larynx at 64.8% (64.8% for males and 64.1% for females) 
• Salivary glands at 70.4% (64.0 % for males and 79.6% for females) 
• Nasal cavity and paranasal sinus at 60.3% (61.2% for males and 58.6% for females) 
(Figure 6.2). 
 
 
Notes 
1. Cancers coded in ICD-10 as C00–C13, C30–C32. 
2. The data for this figure are in Table A6. 
Source: AIHW Australian Cancer Database 2007.  
Figure 6.2: Five-year relative survival, groups of head and neck cancers, persons, Australia,  
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7. Hospitalisations for head and neck 
cancers 
The extent of hospitalisation for cancer is one key measure of the burden of cancer on the 
Australian population. The number of hospitalisations for head and neck cancers in any 1 
year is related not only to the number of people with head and neck cancers, but also the 
number of head and neck cancer-related health services requiring admission to hospital. 
In this report, head and neck cancer-related hospitalisations are defined as those where: 
• the principal diagnosis (the diagnosis that is chiefly responsible for the episode of care) is 
a head and neck cancer (see Appendix A) 
• the principal diagnosis is related to the treatment or management of cancer, and head 
and neck cancer is recorded as an additional diagnosis for that hospitalisation. 
The principal and additional diagnoses are coded using the International statistical 
classifications of disease and related health problems, tenth revision, Australian modification  
(ICD-10-AM), 7th edition. 
The principal diagnosis is usually a disease but can also be a specific treatment of an already 
diagnosed condition such as chemotherapy or radiotherapy for cancer. Where a treatment is 
recorded as the principal diagnosis, the disease being treated is usually recorded as an 
additional diagnosis (NCCH 2010). 
An additional diagnosis is a condition or complaint that either coexists with the principal 
diagnosis or arises during the episode of care. An additional diagnosis is reported if the 
condition affects patient care (AIHW 2013a). 
A hospitalisation is classified as same-day when a patient is admitted and separates (that is, 
completes an episode of care either by being discharged, dying, transferring to another 
hospital or changing type of care) on the same date. A hospitalisation is classified as 
overnight when a patient is admitted to and separated from the hospital on different dates. 
Box 1: Interpreting data on cancer hospitalisations  
The number and rate of head and neck cancer-related chemotherapy procedures may be an 
under-count of actual procedures, due to the admission practices of public hospitals in New 
South Wales, South Australia and the Australian Capital Territory. 
These hospitals provide same-day chemotherapy for outpatients on a non-admitted basis. 
This means that patients who receive same-day chemotherapy treatment for head and neck 
cancers in those hospitals are usually not recorded in the AIHW National Hospital 
Morbidity Database. 
For more information about the AIHW National Hospital Morbidity Database, see the 
National Hospital Morbidity Database data quality statement: 2011–12 
<http://meteor.aihw.gov.au/content/index.phtml/itemId/529483>. 
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Hospitalisations for head and neck cancers 
combined 
In 2011–12, the total number of head and neck cancer-related hospitalisations was 12,609. 
This was 1.4% of all cancer-related hospitalisations (908,034). During these head and neck 
cancer-related hospitalisations, 37,747 procedures were performed. 
In 2011–12, there were 8,478 hospitalisations where head and neck cancer was the principal 
diagnosis. This was an increase of 13.8% from 2002–03 where there were 7,448 head and neck 
cancer hospitalisations. 
In 2011–12, males accounted for a much higher proportion of hospitalisations with a 
principal diagnosis of head and neck cancer with 6,362 hospitalisations (75.0%) compared to 
females at 2,116 (25.0%). 
The age-standardised hospitalisation rate where head and neck cancer was the principal 
diagnosis changed from 37.1 per 100,000 in 2002–03 to 33.9 per 100,000 in 2011–12. Over the 
same period, the age-standardised rate for males changed from 58.3 per 100,000 to 52.7 per 
100,000. For females the age-standardised rate changed from 17.5 per 100,000 to 16.2 per 
100,000 (Figure 7.1). 
  
Notes 
1. Hospitalisations in which the principal diagnosis is one of the head and neck cancers (ICD10-AM codes C00–C14, C30–C32). 
2. Rates were age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
3. The data for this figure are in Table A7. 
Source: AIHW National Hospital Morbidity Database.  
Figure 7.1: Trends in the number of hospitalisations and hospitalisation rates, all head and neck 
cancers combined, by sex, Australia, 2002–03 to 2011–12 
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Hospitalisations for head and neck cancer groups 
Of the 5 head and neck cancer groups, oral cavity accounted for the highest number of 
hospitalisations where head and neck cancer was the principal diagnosis in 2011–12: 
• Oral cavity at 3,659. This was 43.2% of hospitalisations for head and neck cancer.  
• Pharynx at 2,073 (24.5%) 
• Larynx at 1,512 (17.8%) 
• Salivary glands at 608 (7.2%) 
• Nasal cavity and paranasal sinus at 462 (5.4%). 
Overnight hospitalisations were higher than same-day hospitalisations for all head and neck 
cancer groups including: 
• Oral cavity with 2,488 overnight hospitalisations and 1,171 same-day hospitalisations 
• Pharynx with 1,571 overnight and 502 same-day 
• Larynx with 993 overnight and 519 same-day 
• Salivary glands with 538 overnight and 70 same-day 
• Nasal cavity and paranasal sinus with 352 overnight and 110 same-day. 
Males accounted for at least 61% of hospitalisations in each head and neck cancer group in 
2011–12. 
From 2002–03 to 2011–12, the number of hospitalisations where head and neck cancer was 
the principal diagnosis increased for each head and neck cancer group : 
• Oral cavity increased from 2,979 in 2002–03 to 3,659 in 2011–12 
• Pharynx increased from 1,812 to 2,073 
• Larynx increased from 1,441 to 1,512 
• Salivary glands increased from 487 to 608 
• Nasal cavity and paranasal sinus increased from 406 to 462 (Figure 7.2). 
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Notes 
1. Hospitalisations in which the principal diagnosis is head and neck cancer (ICD-10-AM codes C00–C14, C30–C32). 
2. The data for this figure are in Table A8. 
Source: AIHW National Hospital Morbidity Database.  
Figure 7.2: Trends in the number of hospitalisations, groups of head and neck cancers, persons, 
Australia, 2002–03 to 2011–12 
Number of hospitalisations involving surgery 
Australian Refined Diagnosis Related Groups (AR-DRG) have been used as a classification 
system to provide a clinically meaningful way of relating the number and type of patients 
treated in a hospital (that is, its casemix) to the resources that the hospital requires. 
Each AR-DRG represents a class of patient with similar clinical conditions requiring similar 
hospital resources. The AR-DRG system is partly hierarchical, with 23 Major Diagnostic 
Categories, which are divided into Surgical, Medical and Other partitions, and then into 708 
individual AR-DRGs (in AR-DRG version 6.0x). 
From 2002–03 to 2011–12, the number of hospitalisations involving surgery where head and 
neck cancer was the principal diagnosis increased from 3,305 in 2002–03 to 3,725 in 2011–12, 
an overall increase of 12.7%. All head and neck cancer groups had an increase in surgery 
numbers from 2002–03 to 2011–12: 
• Oral cavity cancer increased from 1,817 to 2,012 
• Pharynx increased from 442 to 501 
• Larynx increased from 502 to 590 
• Salivary glands increased from 319 to 402 
• Nasal cavity and paranasal sinus increased from 163 to 198 (Figure 7.3). 
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Notes 
1. Hospitalisations in which the principal diagnosis is head and neck cancer (ICD-10-AM codes C00–C14, C30–C32). 
2. The data for this figure are in Table A9. 
Source: AIHW National Hospital Morbidity Database.  
Figure 7.3: Number of hospitalisations and surgeries, groups of head and neck cancers, persons, 
Australia, 2002–03 and 2011–12 
Chemotherapy and radiotherapy for head and neck 
cancers 
The number of hospitalisations for chemotherapy for head and neck cancers increased from 
2,561 in 2002–03 to 3,952 in 2011–12. 
Over the same period, hospitalisation numbers for radiotherapy for head and neck cancers 
increased from 31 in 2002–03 to 124 in 2011–12 (Table A10). 
Box 2: Hospital admitted cancer-related chemotherapy data 
The number and rate of hospital admitted cancer-related chemotherapy procedures change 
over time due to the admission processes of public hospitals in state and territories. These 
hospitals provide same-day chemotherapy for outpatients on a non-admitted basis. This 
means that patients who receive same-day chemotherapy treatment for cancer in those 
hospitals are usually not recorded in the National Hospitals Morbidity Database and do not 
contribute to hospitals data. 
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Hospitalisation rates for head and neck cancer 
groups 
From 2002–03 to 2011–12, age-standardised hospitalisation rates where head and neck cancer 
was the principal diagnosis varied from year to year, decreasing from 37.1 per 100,000 
persons in 2002–03 to 33.9 per 100,000 persons in 2011–12. 
From 2002–03 to 2011–12, Oral cavity continued to have the highest age-standardised 
hospitalisation rates followed by Pharynx, Larynx, Salivary glands and Nasal cavity and 
paranasal sinuses. Rates remained relatively stable for each group with: 
• Oral cavity at around 15.0 per 100,000 persons 
• Pharynx at around 9.0 per 100,000 persons 
• Larynx at around 7.0 per 100,000 persons 
• Salivary glands at around 2.4 per 100,000 persons 
• Nasal cavity and paranasal sinus at around 1.9 per 100,000 persons (Figure 7.4). 
 
Notes 
1. Hospitalisations in which the principal diagnosis is head and neck cancer (ICD-10-AM codes C00–C14, C30–C32). 
2. Rates were age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
3. The data for this figure are in Table A8. 
Source: AIHW National Hospital Morbidity Database. 
Figure 7.4: Trends in the hospitalisation rates, groups of head and neck cancers, persons, Australia, 
2002–03 to 2011–12 
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Surgery rates for head and neck cancers 
From 2002–03 to 2011–12, the age-standardised hospitalisation rate for hospitalisations 
involving surgery where head and neck cancer was the principal diagnosis increased from 
16.5 per 100,000 in 2002–03 to 18.7 per 100,000 in 2011–12. From 2002–03 to 2011–12, changes 
in hospitalisation rates involving surgery for head and neck cancer groups were: 
• Oral cavity from 9.1 per 100,000 in 2002–03 to 10.0 per 100,000 in 2011–12 
• Pharynx from 2.2 per 100,000 to 2.5 per 100,000 
• Larynx from 2.5 per 100,000 to 2.9 per 100,000 
• Salivary glands from 1.6 per 100,000 to 2.0 per 100,000 
• Nasal cavity and paranasal sinus from 0.8 per 100,000 to 0.9 per 100,000 (Table A9). 
Chemotherapy and radiotherapy rates for head and 
neck cancers 
The age-standardised hospitalisation rate for head and neck cancer involving chemotherapy 
changed from 12.9 per 100,000 in 2002–03 to 19.8 per 100,000 in 2011–12. 
Over the same period, the age-standardised hospitalisation rate for head and neck cancers 
involving radiotherapy changed from 0.1 per 100,000 in 2002–03 to 0.6 per 100,000 in 2011–12 
(Table A10). 
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8. Spotlight on the human papillomavirus 
and head and neck cancer 
What is human papilloma virus? 
Human papillomavirus (HPV) affects human skin and the moist membranes that line the 
body. It is the most common sexually transmitted infection. Sexually transmitted HPVs are 
spread through contact with infected genital skin, mucous membranes, or bodily fluids, and 
can be transmitted through intercourse and oral sex (American Cancer Society 2013). The 
virus can be transmitted between male and female partners as well as same-sex partners—
even when the infected person has no signs or symptoms. 
HPV has been known to contribute to cancer, including cancer of the cervix, vagina, vulva, 
penis and anus (CDCP 2013a). More recently, HPV has been recognised as contributing to 
some cancers of the head and neck. The high-risk HPVs (particularly type 16), have been 
linked to cancers affecting the oral cavity and oropharynx. 
HPV infection often has no symptoms so people infected with the virus may not know they 
have it (CDCP 2013b). The majority of genital HPV cases resolve spontaneously, clearing (i.e. 
no longer detectable) within 12–24 months of initial infection (NCIRS 2013). 
In total, there are over 100 different HPV subtypes of which about 40 are known as genital 
HPV. Some HPV types, including types 16, 18, 31, 33, 35, 45, 52 and 58, are designated as 
‘high risk’, as they are causally associated with the development of cancer. Other HPV types, 
including types 6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81 and 89, have been classified as ‘low risk’ 
and are predominantly associated with non-malignant lesions, such as genital warts. Other 
types are uncommon and their associations with disease are not believed to be significant 
causes of cancer (Munoz et al. 2003). 
Not all of the 40 genital HPV viruses can cause serious health problems. Sexually transmitted 
HPVs fall into two categories: 
• Low-risk HPVs—do not cause cancer but can cause warts on or around the genitals or 
anus. 
• High-risk HPVs—can cause cancer. HPV types 16 and 18, are responsible for the 
majority of HPV-caused cancers (NCI 2012). 
HPV and head and neck cancer 
Over the past 15 years, evidence has been accumulating that implicates HPV as an important 
carcinogenic agent in a subset of head and neck cancers (oral cavity and oropharyngeal 
squamous cell cancers) (Fakhry & Gillison 2006). 
The reported proportions of oropharyngeal cancers associated with HPV vary widely 
ranging from 12% to 63%, with a lower proportion of oral cancers (Adelstein et al. 2009; 
Smith et al. 2004). Of the cancers in these sites that were HPV positive, HPV-16 and/or  
HPV-18 account for more than 85%. 
Recent studies show that about 60%–70% of cancers of the oropharynx may be linked to 
HPV. A mix of tobacco, alcohol and HPV may cause many of these cancers (CDCP 2013c). 
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Head and neck cancers can be evaluated for the presence of HPV, which is useful for 
determining optimal treatment. Typically this is done by testing for the presence of HPV 
DNA in the removed tumour or biopsy (Johns Hopkins Medicines 2013), but other methods 
are being investigated such as surrogate markers for HPV and the usefulness of HPV titres 
(concentration). 
Currently, biopsies of head and neck cancers to ascertain if a lesion contains HPV DNA are 
not routine so complete data are not available on the number of head and neck cancers 
where HPV DVA is present. 
HPV and the Australian National Immunisation 
Program 
During the past decade there has been a greater understanding of the natural history of 
cervical cancer. It is now recognised that cervical cancer is a rare outcome of persistent 
infection with HPV, and that infection with a high-risk HPV type is necessary, although not 
sufficient, for the development of cervical cancer (Bosch et al. 2002; Walboomers et al. 1999). 
Following the discovery that infection with HPV is necessary for the development of cervical 
cancer, the National HPV Vaccination Program (NHVP) was introduced in Australia in 2007. 
Studies have shown a major decrease in HPV infections among the vaccinated group 
(Department of Health 2013b). 
The HPV Vaccination Program provides free HPV vaccination to three groups: 
• girls aged 12–13 in a school-based program, generally delivered in the first year of high 
school 
• boys aged 12–13 in a school-based program, generally delivered in the first year of high 
school 
• boys aged 14–15 as part of a catch-up school-based program, delivered during 2013 and 
2014. 
A national HPV vaccination program register was set up in 2008 to monitor and evaluate the 
HPV Vaccination Program. The register collects data about HPV vaccine doses administered 
in Australia, including selected demographic data, and data on the person who administered 
the vaccine. This ensures patient records of vaccination are up to date and provides a 
resource which immunisation providers can check to confirm a patient’s vaccination history 
(NCI 2012). 
In 2011, the number of girls turning 15 years who participated in the HPV Vaccination 
Program nationally was 322,194, (71.2% of eligible participants) (Department of Health 
2013a). 
There are currently limited published data on the effectiveness of HPV vaccines in reducing 
the incidence of head and neck cancers. However, the introduction of HPV vaccination as a 
public health measure against HPV infection may also result in a favourable impact on the 
frequency of head and neck cancers (Betiol et al. 2013). 
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9. Discussion 
This report presents an overview of incidence, mortality, survival and hospitalisation for 
head and neck cancers. It also discusses risk factors that can contribute to a person 
developing head and neck cancers. 
In this report, head and neck cancer has been separated into 5 groups: 
• Oral cavity 
• Salivary glands 
• Pharynx 
• Nasal cavity and paranasal sinus 
• Larynx. 
Of the 5 groups, the data shows 3 clear groupings in relation to incidence, mortality, and 
hospitalisation numbers and rates. 
Oral cavity cancer accounts for the highest incidence, mortality and hospitalisation numbers 
and rates in all 3 categories. The next highest are the cancer groups Pharynx and Larynx. 
Both of these cancer groups have similar patterns of numbers and rates for incidence, 
mortality and hospitalisations. Finally, Salivary glands and Paranasal sinuses have the 
lowest numbers and rates of incidence, mortality and hospitalisations. 
The age-standardised incidence rate for head and neck cancers in males has decreased from 
32.4 per 100,000 persons in 1982 to 25.9 per 100,000 persons in 2009. Similarly, the  
age-standardised mortality rate of all head and neck cancers in males decreased from 10.0 
per 100,000 persons in 1982 to 6.0 per 100,000 persons in 2011. Five-year relative survival 
increased from 61.8% in 1982–1987 to 68.2% in 2006–2010. These improvements accompany 
reduced smoking rates from 40.3% in 1983 to 16.4% in 2010. Smoking is a risk factor for head 
and neck cancers; however, the lag in time between smoking and the onset of cancer must be 
considered when interpreting these data.  
More Australians born in north-east and south-east Asia are diagnosed with nasopharyngeal 
cancers (a cancer included in the Pharynx group) than would be expected from their 
representation in the general Australian population. 
In 2009, a total of 122 nasopharyngeal cancers were diagnosed in Australia. Of these, 45 were 
diagnosed in people born in north-east or south-east Asia (37%). In comparison, the 
proportion of Australians who were born in north-east or south-east Asia in 2011 was only 
3.25%. 
Viruses, such as Epstein–Barr virus and Cytomegalovirus also have links to head and neck 
cancers (Paradise et al. 2013). 
HPV has been known to contribute to cancer, including cancer of the cervix, vagina, penis 
and anus (CDCP 2013a). More recently, HPV has been recognised as contributing to some 
cancers of the head and neck. The high-risk HPVs (particularly type 16), have been linked to 
cancers affecting oral cavity and pharynx (the area at the back of the throat). Currently, 
biopsies of head and neck cancers are not routine to ascertain if a lesion contains HPV DNA 
so complete data are not available on the number of head and neck cancers where HPV DNA 
is present. 
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In 2007, the Australian Government implemented the National Immunisation Program (NIP) 
designed to protect young women against HPV infections that can lead to various cancers 
including cervical, oral cavity and pharynx cancers later in life (AIHW 2013b). Subsequent 
studies have since shown a substantial drop in HPV-related infection among the vaccinated 
group (Australian Government 2013). A collaborative study that the AIHW and the Victorian 
Cytology Service conducted showed for the first time that the Australian HPV vaccination 
program is preventing cervical pre-cancer lesions in young women (Gertig et al. 2013). In 
2013, the HPV vaccination program was extended to males aged 12–13. Males aged 14–15 
years will also be able to receive the vaccine through a catch-up program in 2013 and 2014. 
The effectiveness of HPV vaccines against head and neck cancers is not conclusive. However, 
the introduction of HPV vaccination as a public health measure against HPV infection may 
also result in a favourable impact on the frequency of head and neck cancers (Betiol et al. 
2013). 
Head and neck cancers are less common cancers and, as such, don’t always receive the same 
attention as other more common cancers. Many head and neck cancers can be attributed to 
lifestyle factors including smoking, excess alcohol consumption, poor diet and excess sun 
exposure. Therefore, altering lifestyle behaviours can play a major role in reducing the 
number of head and neck cancers diagnosed. 
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Appendix A 
Defining head and neck cancers 
Head and neck cancers are defined for use in AIHW reporting in consultation with the 
Australasian Association of Cancer Registries (AACR), using the ICD codes/groups 
described in Table 1. 
Table 1: Head and neck cancers, AIHW/AACR, ICD-10/ICD-10-AM and ICD-9 codes  
Broad grouping Sub-grouping Site 
ICD-10/ 
ICD-10-AM 
code ICD-9 code 
Oral cavity 
Lip Malignant neoplasm of lip  C00 140 
Tongue 
Malignant neoplasm of base of tongue  C01 141.0 
Malignant neoplasm of other and 
unspecified parts of tongue  C02 141.1–141.9 
Other oral cavity 
Malignant neoplasm of gum  C03 143 
Malignant neoplasm of floor of mouth  C04 144 
Malignant neoplasm of palate  C05 145.2, 145.3, 145.5 
Malignant neoplasm of other and 
unspecified parts of mouth C06 
145.0, 145.1, 
145.4, 
145.6–145.9 
Salivary glands 
Malignant neoplasm of parotid gland C07 142.0 
Malignant neoplasm of other and 
unspecified major salivary glands C08 142.1–142.9 
Pharynx 
Oropharynx, including tonsil 
Malignant neoplasm of tonsil C09 146.0 
Malignant neoplasm of oropharynx C10 146.1–146.9 
Nasopharynx Malignant neoplasm of nasopharynx C11 147 
Hypopharynx, including 
piriform sinus 
Malignant neoplasm of piriform sinus C12 148.1 
Malignant neoplasm of hypopharynx C13 148.0, 148.2–148.9 
Other and ill-defined sites in lip, oral cavity and pharynx C14 149 
Nasal cavity and 
paranasal sinus 
 Malignant neoplasm of nasal cavity and middle ear C30 
160 
 Malignant neoplasm of accessory sinuses C31 
Larynx  Malignant neoplasm of larynx C32 161 
Notes 
1. ICD-9 codes were used in analysis of mortality data. 
2. ICD-10 codes were used in analysis of incidence and survival data.  
3. ICD-10-AM codes were used in analysis of hospitalisation data. 
4. Hospitalisation data excludes separations with care type of newborns with only unqualified days, hospital boarders and posthumous organ 
procurement. 
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Appendix B 
Australian Cancer Database 2009 Data Quality 
Statement 
Identifying and definitional attributes 
Metadata item type: Quality statement 
Synonymous names: ACD 2009 
METeOR identifier: 500417 
Registration status: AIHW Data Quality Statements, Endorsed 11/12/2012 
Data quality 
Quality statement: 
Important note 
To avoid excessive repetition in what follows, the word ‘cancer’ is used to mean ‘cancer, 
excluding basal cell carcinomas of the skin and squamous cell carcinomas of the skin’. In 
most states and territories these 2 very common skin cancers are not notifiable diseases and 
as such are not in the scope of the Australian Cancer Database (ACD). 
Summary of key issues 
• All states and territories maintain a population-based cancer registry to which all cancer 
cases and deaths must be reported.  
• The AIHW compiles the ACD using information from state and territory registers.  
• Some duplication may occur where the same person and cancer have been registered in 2 
or more jurisdictions. The AIHW provisionally resolves these instances and notifies the 
relevant states and territories of possible duplicates. Full resolution has usually occurred 
by the following year’s version of the ACD.  
• The level of duplication is small, about 0.17% of all records.  
• Cancer registry databases change every day, adding new records and improving the 
quality of existing records as new information becomes available. Information on ACD 
records may therefore change from year to year. 
Description 
All states and territories have legislation that makes cancer a notifiable disease. All hospitals, 
pathology laboratories, radiotherapy centres and registries of births, deaths and marriages 
must report cancer cases and deaths to the state or territory population-based cancer registry. 
Each registry supplies incidence data annually to the AIHW under an agreement between 
the registries and the AIHW. These data are compiled into the ACD, the only Australian 
repository of national cancer incidence data. 
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Institutional environment: 
The Australian Institute of Health and Welfare (AIHW) is a major national agency set up by 
the Australian Government under the Australian Institute of Health and Welfare Act 1987 to 
provide reliable, regular and relevant information and statistics on Australia’s health and 
welfare. It is an independent statutory authority established in 1987, governed by a 
management board, and accountable to the Australian Parliament through the Health 
portfolio. 
The AIHW aims to improve the health and wellbeing of Australians through better health 
and welfare information and statistics. It collects and reports information on a wide range of 
topics and issues, ranging from health and welfare expenditure, hospitals, disease and 
injury, and mental health, to ageing, homelessness, disability and child protection. 
The Institute also plays a role in developing and maintaining national metadata standards. 
This work contributes to improving the quality and consistency of national health and 
welfare statistics. The Institute works closely with governments and non-government 
organisations to achieve greater adherence to these standards in administrative data 
collections, to promote national consistency and comparability of data and reporting. 
One of the main functions of the AIHW is to work with the states and territories to improve 
the quality of administrative data and, where possible, to compile national data sets based on 
data from each jurisdiction, to analyse these data sets and disseminate information and 
statistics. 
The Australian Institute of Health and Welfare Act 1987, in conjunction with compliance to the 
Privacy Act 1988 (Commonwealth), ensures that the data collections that the AIHW manages 
are kept securely and under the strictest conditions with respect to privacy and 
confidentiality. 
For further information, see the AIHW website <www.aihw.gov.au.>. 
The AIHW has been maintaining the ACD since 1986. 
Relevance: 
The ACD is highly relevant for monitoring trends in cancer incidence. The data are used for 
many purposes, such as by policy makers to evaluate health intervention programs and as 
background data for health labour force planning and health expenditure; by pharmaceutical 
companies to assess the size of the market for new drugs; by researchers to explore the 
epidemiology of cancer; by insurance companies to evaluate the risk of people being 
diagnosed with cancer. 
The ACD contains information on all reported cancer cases and deaths in Australia. Data can 
be provided at state and territory level and at Remoteness Area level. 
The 3rd edition of the International Classification of Diseases for Oncology (ICD-O-3) is used 
to classify cancer cases. Data can also be classified according to the 10th revision of the 
International Statistical Classification of Diseases and Related Health Problems (ICD-10). 
The ACD also contains the name and date of birth of each person diagnosed with cancer. 
This allows researchers who have enrolled people in a study to link their database to the 
ACD to find out which of their study subjects have been diagnosed with cancer, what kind of 
cancer, and when. (Such data linkage can only be undertaken after receiving approvals from 
various ethics committees.) This kind of research gives insight into cancer risk factors. Data 
linkage is also undertaken when a researcher has been contracted to investigate a potential 
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cancer cluster in a workplace or small area. 
Timeliness: 
This data quality statement refers to the 2009 version of the ACD, which contains data on all 
cancer cases diagnosed between 1982 and 2009. However, the number of cases in 2009 for 
NSW and the ACT was estimated (see ‘Accuracy’ section below). 
Each jurisdictional cancer registry supplies data annually to the AIHW. Because each 
jurisdiction operates on its own data compilation and reporting cycle, the ACD cannot be 
fully compiled until the final jurisdiction supplies its data. 
It generally takes a year or more for the state and territory cancer registries to fully process 
and release their latest full year of cancer data to the AIHW. Once the AIHW receives all the 
data sets from cancer registries, time is needed to check for data consistency and to 
deduplicate the data before the new version of the ACD is available for reporting purposes.   
Accuracy: 
The 1982–2009 data files for NSW and the ACT were not available for inclusion in the 2009 
version of the ACD. An extended delay of the receipt of mortality data has meant that NSW 
and the ACT have not been able to close off their 2009 data sets. As a consequence, 2009 
cancer data for these jurisdictions are not available for reporting purposes. The AIHW 
estimated the 2009 incidence data for NSW and the ACT in consultation with the NSW and 
ACT cancer registries. The estimates were combined with the actual data that these two 
jurisdictions supplied for the 2008 ACD to form their 1982–2009 data sets for inclusion in the 
2009 ACD. Although the estimation procedure has been shown to be reasonably accurate for 
estimating overall cancer incidence, its accuracy with respect to individual cancers will vary. 
As NSW and ACT make up about a third of Australia’s population, the national incidence 
data for 2009 is likely to be somewhat inaccurate for some individual cancers—which cancers 
these are is not predictable.  
It is anticipated that future versions of the ACD will include 2009 actual data for NSW and 
ACT and the data will then be made available in subsequent cancer publications.  
The publication Cancer incidence in five continents is issued about every 5 years as a 
collaborative effort by the International Agency for Research on Cancer (IARC) and the 
worldwide network of cancer registries. Australia’s cancer registries continue to pass IARC’s 
numerous tests for data quality. Details of the tests and Australia’s cancer registries’ results 
in them can be found in the  
above-mentioned book and the registries’ annual incidence reports. 
Each year, when all the registries’ new data have been compiled into the new ACD, a data 
linkage process called the national deduplication is undertaken. This process detects 
instances where the same person and cancer have been registered in two or more 
jurisdictions. This could happen, for example, when a person attends hospitals in different 
jurisdictions. All such instances that are found are provisionally resolved at the AIHW by 
removing one record while the relevant jurisdictions are notified of the situation so that they 
can determine in which jurisdiction the person was a usual resident at the time of diagnosis. 
Their resolution will flow through to the ACD in the next year’s data supply. In recent years 
the national deduplication has resulted in the removal of about 3,500 records from the ACD, 
which is about 0.17% of all records that the jurisdictions supplied. 
While all state and territory cancer registries collect information on Indigenous status, in 
some jurisdictions the level of identification of Indigenous Australians is considered to be 
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insufficient to enable analysis. Data for 4 states and territories—New South Wales, 
Queensland, Western Australia and the Northern Territory—are considered suitable for 
analysis. 
Cancer registry databases change every day, and not just because new records are added. 
Existing records are changed if new, more precise, information about the diagnosis becomes 
available. Also, any typographical errors that routine data checking procedures discover are 
corrected by referring to the source documentation. Finally, existing records can be deleted if 
it is discovered that the initial diagnosis of cancer was incorrect (for example, the tumour 
was in fact benign) or the person is found to be not a resident of that state or territory. As a 
result of all these issues, the number of cancer cases that the AIHW reports for any particular 
year may change slightly over time, and data that a cancer registry publishes at a certain 
time may differ slightly from what the AIHW publishes at a different time.  
Coherence: 
The AIHW reports and publishes cancer data annually. While there are sometimes changes 
to coding for particular cancers, it is possible to map coding changes to make meaningful 
comparisons over time. 
Interpretability: 
Information on the ACD is available on the AIHW website. 
While numbers of new cancers are easy to interpret, other statistical calculations (for 
example, calculations of  
age-standardised rates and confidence intervals) are more complex and their concepts may 
be confusing to some users. In most publications, there is an appendix on statistical methods 
as well as technical notes. 
Accessibility: 
The AIHW website provides cancer incidence and mortality data that can be downloaded 
without charge. Numerous reports, including the biennial Cancer in Australia, are published 
and are available on the AIHW website where they can also be downloaded without charge. 
Users can request data not available online or in reports via the Cancer and Screening Unit of 
the AIHW on (02) 6244 1000 or via email to <cancer@aihw.gov.au>. Requests that take longer 
than half an hour to compile are charged for on a cost-recovery basis. General enquiries 
about AIHW publications can be made to the Media and Strategic Engagement Unit on (02) 
6244 1032 or via email to <info@aihw.gov.au>. 
Researchers following a cohort of people enrolled in a longitudinal study of health outcomes 
can request the AIHW to undertake data linkage of their cohort to the ACD. The AIHW 
Ethics Committee, as well as the ethics committees governing access to the state and territory 
cancer registries, must approve such requests. 
Source and reference attributes 
Submitting organisation: Australian Institute of Health and Welfare 
Steward: Australian Institute of Health and Welfare 
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Relational attributes 
Related metadata references: 
See also Australian Cancer Database 2008 Data Quality Statement AIHW Data Quality 
Statements, Endorsed 20/07/2012. 
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Tables 
Table A1: Smoking rates by sex, Australia, 1964–2010 
Year Males Females 
1964 58.0 28.0 
1966 55.0 26.0 
1969 45.0 28.0 
1974 45.3 29.6 
1976 43.9 32.5 
1980 41.1 31.1 
1983 40.3 30.9 
1986 32.9 28.5 
1989 30.2 27.0 
1992 28.2 23.8 
1995 26.3 22.0 
1998 24.4 19.8 
2001 21.4 18.2 
2004 18.6 16.3 
2007 18.0 15.2 
2010 16.4 13.9 
Notes  
1. Smoked at least 100 cigarettes (manufactured and/or roll-your-own) or the equivalent amount of tobacco in their life, and reports no longer 
smoking.  
2. Never smoked 100 cigarettes (manufactured and/or roll-your-own) or the equivalent amount of tobacco.  
3. Some trend data were updated in 2010 and may not match data presented in previous reports. 
Source: OECD health data, 2013. 
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Table A2: Incidence numbers and rates, and mortality numbers and rates of all head and neck 
cancers combined, persons, Australia, 1982–2011 
Year Number of new cases Incidence rate Number of deaths  Mortality rate Mortality/Incidence ratio 
1982 2,475 19.3 752 6.1 0.32 
1983 2,573 19.7 757 5.9 0.30 
1984 2,578 19.3 897 6.9 0.36 
1985 2,666 19.6 880 6.6 0.34 
1986 2,610 18.8 851 6.2 0.33 
1987 2,847 20.1 922 6.6 0.33 
1988 2,876 19.8 862 6.0 0.30 
1989 3,048 20.5 921 6.2 0.30 
1990 3,034 20.0 927 6.2 0.31 
1991 3,145 20.3 983 6.5 0.32 
1992 3,482 22.0 964 6.1 0.28 
1993 3,257 20.2 956 6.0 0.30 
1994 3,219 19.6 945 5.8 0.30 
1995 3,368 20.1 907 5.5 0.27 
1996 3,430 20.0 1,011 6.0 0.30 
1997 3,581 20.4 898 5.1 0.25 
1998 3,615 20.2 896 5.0 0.25 
1999 3,385 18.5 939 5.1 0.28 
2000 3,441 18.3 946 5.0 0.27 
2001 3,385 17.6 988 5.1 0.29 
2002 3,518 17.8 948 4.8 0.27 
2003 3,515 17.4 931 4.6 0.26 
2004 3,429 16.7 887 4.3 0.26 
2005 3,545 16.8 902 4.3 0.26 
2006 3,680 17.2 838 3.9 0.23 
2007 3,767 17.0 919 4.1 0.24 
2008 3,722 16.5 947 4.1 0.25 
2009 3,896 16.8 990 4.3 0.26 
2010   1,030 4.3  
2011   944 3.8  
Notes 
1. Cancers coded in ICD-10 as C00–C14, C30–C32. 
2. Deaths registered in 2009 and earlier are based on the final version of cause of death data; deaths registered in 2010 and 2011 are based 
on revised and preliminary versions, respectively and are subject to further revision. 
3. Rates are age-standardised to the estimated resident population of Australia for 30 June 2001 and expressed per 100,000 population. 
4. The mortality data in AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the National 
Coronial Information System and coded by the Australian Bureau of Statistics. 
5. Years in table refer to year of occurrence of death except for the most recent year, which refers to the year of registration of death. 
6. Rates are per 100,000. 
Source: AIHW Australian Cancer Database 2009 and AIHW National Mortality Database. 
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Table A3: Incidence numbers and rates and mortality numbers and rates of all head and neck 
cancers combined, by sex, Australia, 1982–2011 
Year 
Number of 
new cases 
Incidence 
rate 
Number of 
deaths  
Mortality 
rate 
Number of 
new cases 
Incidence 
rate 
Number of 
deaths  
Mortality 
rate 
 Males Females 
1982 1,943 32.4 570 10.0 532 7.9 182 2.8 
1983 2,007 32.9 591 10.1 566 8.2 166 2.4 
1984 2,015 32.7 689 11.7 563 8.1 208 3.0 
1985 2,061 32.4 696 11.9 605 8.4 184 2.6 
1986 2,018 31.2 643 10.1 592 7.9 208 2.8 
1987 2,177 32.9 686 10.7 670 8.9 236 3.0 
1988 2,212 32.7 657 10.0 664 8.5 205 2.6 
1989 2,348 33.8 706 10.5 700 8.8 215 2.7 
1990 2,285 32.0 717 10.5 749 9.3 210 2.6 
1991 2,361 32.6 730 10.5 784 9.5 253 3.0 
1992 2,623 35.6 757 10.4 859 10.1 207 2.4 
1993 2,492 33.1 713 9.8 765 8.9 243 2.8 
1994 2,384 31.1 707 9.4 835 9.5 238 2.7 
1995 2,481 31.6 691 9.2 887 9.9 216 2.4 
1996 2,521 31.4 762 9.8 909 9.9 249 2.7 
1997 2,609 31.9 682 8.6 972 10.3 216 2.2 
1998 2,653 31.6 685 8.4 962 10.0 211 2.1 
1999 2,453 28.4 688 8.3 932 9.5 251 2.4 
2000 2,487 28.1 696 8.1 954 9.5 250 2.4 
2001 2,490 27.4 754 8.5 895 8.7 234 2.2 
2002 2,565 27.5 714 8.0 953 9.1 234 2.1 
2003 2,590 27.0 676 7.3 925 8.6 255 2.3 
2004 2,485 25.5 666 7.0 944 8.6 221 1.9 
2005 2,577 25.8 688 7.0 968 8.6 214 1.9 
2006 2,736 26.9 654 6.5 944 8.3 184 1.6 
2007 2,767 26.4 679 6.6 1,000 8.5 240 1.9 
2008 2,688 25.0 702 6.7 1,034 8.6 245 1.9 
2009 2,875 25.9 741 6.8 1,021 8.4 249 2.0 
2010   772 6.9   258 1.9 
2011   691 6.0   253 1.8 
Notes 
1. Cancers coded in ICD-10 as C00–C14, C30–C32. 
2. Deaths registered in 2009 and earlier are based on the final version of cause of death data; deaths registered in 2010 and 2011 are based 
on revised and preliminary versions, respectively and are subject to further revision. 
3. Rates are age-standardised to the estimated resident population of Australia for 30 June 2001 and expressed per 100,000 population. 
4. The mortality data in AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the National 
Coronial Information System and coded by the Australian Bureau of Statistics. 
5. Years in table refer to year of occurrence of death except for the most recent year, which refers to the year of registration of death. 
Source: AIHW Australian Cancer Database 2009 and AIHW National Mortality Database. 
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Table A4: Incidence numbers and rates of groups of head and neck cancers, persons, Australia,  
1982–2009 
 Oral cavity Salivary glands Pharynx 
Nasal cavity and 
paranasal sinus Larynx 
Year 
Incidence 
number   Rate 
Incidence 
number   Rate 
Incidence 
number   Rate 
Incidence 
number   Rate 
Incidence 
number  
  
Rate 
1982 1,263 9.9 152 1.2 378 2.9 96 0.8 553 4.3 
1983 1,300 10.0 124 1.0 433 3.3 82 0.7 600 4.5 
1984 1,262 9.4 158 1.2 453 3.3 120 0.9 549 4.1 
1985 1,380 10.2 167 1.3 444 3.2 102 0.8 525 3.8 
1986 1,270 9.2 159 1.2 483 3.5 102 0.7 566 4.0 
1987 1,502 10.7 148 1.1 459 3.2 87 0.6 594 4.2 
1988 1,538 10.6 151 1.0 454 3.1 98 0.7 581 3.9 
1989 1,605 10.9 190 1.3 497 3.3 109 0.7 600 4.0 
1990 1,628 10.8 161 1.1 495 3.2 110 0.7 601 3.9 
1991 1,712 11.1 170 1.1 496 3.2 122 0.8 579 3.7 
1992 1,918 12.1 192 1.3 511 3.2 112 0.7 675 4.3 
1993 1,772 11.0 179 1.1 513 3.2 139 0.9 589 3.6 
1994 1,787 10.9 194 1.2 504 3.0 123 0.8 556 3.4 
1995 1,857 11.1 186 1.1 549 3.3 117 0.7 596 3.6 
1996 1,969 11.5 183 1.1 518 3.0 122 0.7 578 3.4 
1997 2,094 12.0 210 1.2 483 2.7 133 0.8 587 3.4 
1998 2,050 11.4 217 1.2 535 3.0 125 0.7 623 3.5 
1999 1,811 9.9 213 1.2 600 3.3 124 0.7 568 3.1 
2000 1,846 9.8 239 1.3 566 3.0 145 0.8 561 3.0 
2001 1,835 9.5 240 1.2 525 2.7 126 0.7 583 3.0 
2002 1,974 10.0 214 1.1 577 2.9 131 0.7 541 2.7 
2003 1,974 9.8 234 1.2 536 2.7 130 0.6 567 2.8 
2004 1,837 8.9 243 1.2 546 2.7 137 0.7 601 2.9 
2005 1,830 8.7 260 1.2 605 2.9 173 0.8 590 2.8 
2006 1,908 8.9 265 1.2 654 3.0 149 0.7 622 2.9 
2007 2,012 9.1 291 1.3 643 2.9 155 0.7 583 2.6 
2008 1,933 8.6 274 1.2 683 3.0 174 0.8 589 2.6 
2009 2,037 8.8 265 1.1 739 3.2 166 0.7 606 2.6 
Notes 
1. Cancers coded in ICD-10 as C00–C13, C30–C32. 
2. Rates are age-standardised to the estimated resident population of Australia for 30 June 2001 and expressed per 100,000 population. 
Source: AIHW Australian Cancer Database 2009. 
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Table A5: Mortality numbers and rates of groups of head and neck cancers, persons, Australia,  
1982–2011 
 Oral cavity Salivary glands Pharynx 
Nasal cavity and 
paranasal sinus Larynx 
Year 
Number of 
deaths   Rate 
Number of 
deaths   Rate 
Number of 
deaths   Rate 
Number of 
deaths   Rate 
Number of 
deaths 
  
Rate 
1982 237 1.4 40 0.2 217 1.2 47 0.3 192 1.1 
1983 260 1.5 48 0.3 193 1.1 40 0.2 203 1.1 
1984 304 1.7 58 0.3 222 1.2 44 0.2 239 1.3 
1985 309 1.7 59 0.3 214 1.2 45 0.2 217 1.2 
1986 277 1.5 56 0.3 215 1.2 44 0.2 228 1.2 
1987 303 1.6 45 0.2 255 1.4 41 0.2 247 1.3 
1988 301 1.6 60 0.3 238 1.3 25 0.1 211 1.1 
1989 313 1.7 54 0.3 248 1.3 42 0.2 238 1.3 
1990 321 1.7 50 0.3 248 1.3 37 0.2 251 1.3 
1991 314 1.6 72 0.4 271 1.4 43 0.2 256 1.3 
1992 318 1.6 43 0.2 264 1.4 50 0.3 264 1.4 
1993 296 1.5 62 0.3 268 1.4 48 0.2 247 1.3 
1994 317 1.6 62 0.3 262 1.3 41 0.2 239 1.2 
1995 311 1.6 64 0.3 244 1.2 38 0.2 226 1.2 
1996 322 1.6 78 0.4 283 1.4 47 0.2 248 1.3 
1997 269 1.4 49 0.3 256 1.3 30 0.2 256 1.3 
1998 307 1.6 73 0.4 229 1.2 53 0.3 198 1.0 
1999 316 1.6 49 0.3 240 1.2 34 0.2 245 1.3 
2000 326 1.7 57 0.3 250 1.3 36 0.2 239 1.2 
2001 326 1.7 59 0.3 261 1.4 45 0.2 248 1.3 
2002 302 1.6 88 0.5 234 1.2 37 0.2 241 1.3 
2003 305 1.6 72 0.4 221 1.2 33 0.2 224 1.2 
2004 275 1.4 66 0.3 203 1.1 44 0.2 218 1.1 
2005 269 1.4 81 0.4 225 1.2 35 0.2 214 1.1 
2006 270 1.4 61 0.3 191 1.0 27 0.1 203 1.0 
2007 328 1.6 66 0.3 210 1.0 22 0.1 220 1.1 
2008 305 1.5 89 0.4 208 1.0 27 0.1 229 1.1 
2009 311 1.4 80 0.4 270 1.3 32 0.1 214 1.0 
2010 323 1.5 82 0.4 252 1.1 38 0.2 254 1.2 
2011 294 1.3 79 0.4 238 1.1 37 0.2 207 0.9 
Notes 
1. Deaths registered in 2009 and earlier are based on the final version of cause of death data; deaths registered in 2010 and 2011 are based 
on revised and preliminary versions, respectively and are subject to further revision. 
2. Cancers coded in ICD-10 as C00–C13, C30–C32. 
3. Rates are age-standardised to the estimated resident population of Australia for 30 June 2001 and expressed per 100,000 population. 
4. The mortality data in AIHW National Mortality Database were provided by the Registries of Births, Deaths and Marriages and the National 
Coronial Information System and coded by the Australian Bureau of Statistics. 
Source: AIHW National Mortality Database. 
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Table A6: One-year and 5-year relative survival after diagnosis, head and neck cancer groups, by 
sex, Australia, 2006–2010 
Head and neck cancer group  1-year relative survival 5-year relative survival 
 Males Females Persons Males Females Persons 
Oral cavity 90.5 88.1 89.8 75.6 73.8 75.0 
Salivary glands 89.8 92.3 90.8 64.0 79.6 70.4 
Pharynx 80.1 78.7 79.8 54.8 58.2 55.5 
Nasal cavity and paranasal sinus 83.3 78.7 81.7 61.2 58.6 60.3 
Larynx 86.3 88.0 86.4 64.8 64.1 64.8 
All head and neck combined 86.7 86.3 86.6 67.4 70.4 68.2 
Note: Cancers coded in ICD-10 as C00–C14, C30–C32. 
Source: AIHW Australian Cancer Database 2007. 
Table A7: Hospitalisation numbers and rates for all head and neck cancers combined, by sex, 
Australia, 2002–03 to 2011–12 
Year Males Females 
 Number Rate Number Rate 
2002–03 5,595 58.3 1,853 17.5 
2003–04 5,622 57.3 1,830 17.0 
2004–05 5,885 58.7 1,791 16.3 
2005–06 6,170 60.2 2,035 18.0 
2006–07 6,326 60.3 2,082 18.1 
2007–08 6,123 57.2 2,041 17.2 
2008–09 5,786 52.4 1,918 15.9 
2009–10 6,173 54.3 2,077 16.9 
2010–11 6,245 53.5 2,068 16.3 
2011–12 6,362 52.7 2,116 16.2 
Notes 
1. Hospitalisations in which the principal diagnosis is one of the head and neck cancers (ICD-10-AM codes C00–C14, C30–C32). 
2. Rates were age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Source: AIHW National Hospital Morbidity Database.   
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Table A8: Hospitalisation numbers and rates for groups of head and neck cancers and all head and 
neck cancers combined, persons, Australia, 2002–03 to 2011–12 
Year Oral cavity Salivary glands Pharynx 
Nasal cavity 
and paranasal 
sinus Larynx 
All head and 
neck 
 No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate 
2002–03 2,979 14.9 487 2.4 1,812 9.0 406 2.0 1,441 7.2 7,448 37.1 
2003–04 3,002 14.7 464 2.2 1,893 9.2 390 1.9 1,475 7.2 7,452 36.3 
2004–05 2,995 14.3 497 2.4 2,009 9.7 409 2.0 1,562 7.5 7,677 36.7 
2005–06 3,444 16.1 561 2.6 2,009 9.4 401 1.8 1,553 7.2 8,205 38.2 
2006–07 3,276 15.0 620 2.8 2,072 9.5 399 1.8 1,774 8.0 8,408 38.3 
2007–08 3,384 15.2 590 2.6 2,001 9.0 417 1.8 1,554 6.9 8,164 36.4 
2008–09 3,168 13.8 587 2.5 1,896 8.2 365 1.5 1,465 6.3 7,704 33.3 
2009–10 3,277 13.9 667 2.8 2,094 8.9 473 2.0 1,530 6.4 8,250 34.8 
2010–11 3,446 14.2 647 2.6 2,152 8.9 466 1.9 1,401 5.7 8,313 34.2 
2011–12 3,659 14.6 608 2.4 2,073 8.4 462 1.9 1,512 6.0 8,478 33.9 
Notes 
1. Hospitalisations in which the principal diagnosis is one of the head and neck cancers (ICD-10-AM codes C00–C14, C30–C32). 
2. Rates were age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population. 
Source: AIHW National Hospital Morbidity Database.  
Table A9: Number of hospitalisations and surgeries, groups of head and neck  
cancers, persons, Australia, 2002–03 and 2011–12 
Cancer group 2002–03 2011–12 
 
Surgery 
Other 
hospitalisation Surgery 
Other 
hospitalisation 
 Number Rate Number Number Rate Number 
Oral cavity 1,817 9.1 1,162 2,012 10.0 1,647 
Salivary glands 319 1.6 168 402 2.0 206 
Pharynx 442 2.2 1,370 501 2.5 1,572 
Nasal cavity and paranasal sinus 163 0.8 243 198 0.9 264 
Larynx 502 2.5 939 590 2.9 922 
All head and neck cancers 3,305 16.5 4,143 3,725 18.7 4,753 
Notes  
1. Hospitalisations in which the principal diagnosis is head and neck cancer (ICD-10-AM codes C00–C14, C30–C32). 
2. Rates were age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population 
Source: AIHW National Hospital Morbidity Database.   
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Table A10: Number and rate of chemotherapy and radiotherapy, head and neck cancers,  
Australia, 2002–03 and 2011–12 
Treatment 2002–03 2011–12 
 Number Rate Number Rate 
Chemotherapy 2,561 12.9 3,952 19.8 
Radiotherapy 31 0.1 124 0.6 
Notes  
1. Hospitalisations in which the principal diagnosis is head and neck cancer (ICD-10-AM codes C00–C14, C30–C32). 
2. Rates were age-standardised to the Australian population as at 30 June 2001 and expressed per 100,000 population 
Source: AIHW National Hospital Morbidity Database.   
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Glossary 
Age-standardisation: A method of moving the influence of age when comparing 
populations with different age structures. This is usually necessary because the rates of many 
diseases vary strongly (usually increasing) with age. The structures of the different 
populations are converted to the same ‘standard’ structure; then the disease rates that would 
have occurred with that structure are calculated and compared. 
Benign: Non-cancerous tumours that may grow larger but do not spread to other parts of the 
body. 
Cancer (malignant neoplasm): A large range of diseases in which some of the body’s cells 
become defective, begin to multiply out of control, can invade and damage the area around 
them, and can spread to other parts of the body to cause further damage. 
Current smoker: A person who reported currently smoking daily, weekly or less often than 
weekly. 
Hospitalisation: An episode of care for an admitted patient which may include a total 
hospital stay (from admission to discharge, transfer or death) or a portion of a hospital stay 
that begin or ends in a change of type of care (for example, from acute to rehabilitation). 
Hypopharynx: The lowest part of the throat and behind the voice box. 
Ill-defined head and neck cancers: Head and neck cancers which it is not possible to classify 
into one of the other 5 head and neck cancer groups. These head and neck cancers are 
included in the totals in this report but are not presented separately. 
Incidence: The number of new cases (of an illness or event, and so on) in a given period. 
Larynx: The larynx, also called the voice box, is a short passageway formed by cartilage just 
below the pharynx in the neck.  
Malignant: A tumour with the capacity to spread to surrounding tissue or to other sites in 
the body. 
Metastasis: the process by which cancerous cells are transferred from one part of the body to 
another, for example, via the lymphatic system or the bloodstream. 
Nasal cavity and paranasal sinus: The paranasal sinuses are small hollow spaces in the 
bones of the head surrounding the nose. The nasal cavity is the hollow space inside the nose. 
This group also includes the middle ear. 
Nasopharynx: The upper part of the pharynx, comprising the cavity behind the nose and 
above the soft palate. 
Neoplasm: An abnormal (‘neo’, new) growth of tissue. Can be ‘benign’ (not a cancer) or 
‘malignant’ (a cancer). Also known as a tumour. 
Never-smoker: A person who does not smoke now and has smoked fewer than 100 
cigarettes or the equivalent tobacco in his or her lifetime. 
Oral cavity: The oral cavity includes the lips, tongue, and other areas within the oral cavity 
including the gums, floor of the mouth, the palate (roof of the mouth) and other unspecified 
parts of the mouth. 
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Oropharynx: The middle part of the pharynx, including the soft palate (the back of the 
mouth), the base of the tongue, and the tonsils. 
Other cancers in the head and neck region: Cancers of the brain, eye, oesophagus, thyroid 
and parathyroid glands, as well as those of the scalp, skin, muscles and bones of the head 
and neck are generally not classified as head and neck cancers and are not included within 
this report. 
Pharynx: The pharynx (throat) is a hollow tube that starts behind the nose and leads to the 
oesophagus. It has three parts:  
• Nasopharynx—the upper part of the pharynx, cavity behind the nose and above the soft 
palate 
• Oropharynx—the middle part of the pharynx, including the soft palate (the back of the 
mouth), the base of the tongue, and the tonsils 
• Hypopharynx—the lowest part of the throat and behind the voice box. 
Risk factor: Any factor that represents a greater risk of a health disorder or other unwanted 
condition or event. Some risk factors are regarded as causes of disease, others are not. 
Salivary glands: The major salivary glands are in the floor of the mouth beneath the tongue 
(sublingual gland), near the ear (parotid gland) and near the jawbone (submandibular 
gland). There are other minor salivary glands located throughout the oral cavity. 
Survival: A general term indicating the probability of being alive for a given amount of time 
after a particular event, such as a diagnosis of cancer. 
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Head and neck cancers in AustraliaHead and neck cancers in Australia, presents the latest available information on incidence, mortality, survival 
and hospitalisations.
Findings include:
•   The total number of head and neck cancers diagnosed 
in 2009 was 3,896 accounting for 3.4% of all cancers 
diagnosed (114,137).
•   The total number of deaths from head and neck  
cancers in 2011 was 944 accounting for 2.2% of all 
deaths from cancer (43,221).
•   In 2006–2010, 5–year relative survival was 68.2% for all 
head and neck cancers combined.
•   In 2011–12 there were 8,478 hospitalisations where 
head and neck cancer was the principal diagnosis.
